| 摘要 |
The disclosure relates to methods of treating an infant at risk of developing bronchopulmonary dysplasia, including premature infants, by administering a TGF-βantagonist during the perinatal period, including the prenatal period and/or the postnatal period. For administration during the prenatal period, the TGF-βantagonist can be administered either directly to the infant in utero, or indirectly by administration to the mother. |
